Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01432600 · ClinicalTrials.gov registry record · Phase 1
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT01432600 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 80 participants.
The verdict
NCT01432600, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The main purpose of this study is to see whether pomalidomide can help people with myeloma. Researchers also want to find out if pomalidomide is safe and tolerable.
Interventions
- DRUG Cyclophosphamide
- DRUG Dexamethasone
- DRUG Pomalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2011-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01432600
The ClinicalTrials.gov registry entry for NCT01432600 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT01432600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01432600 about?
NCT01432600 is a clinical study titled "Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide". The main purpose of this study is to see whether pomalidomide can help people with myeloma. Researchers also want to find out if pomalidomide is safe and tolerable.
What is the current status of trial NCT01432600?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2011-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01432600?
The interventions under investigation include: Cyclophosphamide (DRUG), Dexamethasone (DRUG), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT01432600?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.